IEIH
iShares Evolved U.S. Innovative Healthcare ETFIEIH Fund Description
IEIH tracks an index that offers US pharmaceutical and biotechnology exposure as defined by the iETF Evolved Sector classification scheme.
IEIH Factset Analytics Insight
IEIH makes use of iShares’ “Evolved” sector classification scheme to provide exposure to a subset of the traditional US healthcare sector. Unlike traditional classification schemes, firms may be classified into more than one sector under the Evolved Sector system. Sector assignments are made using proprietary machine learning models. In this case, IEIH offers exposure to firms traditionally classified as pharmaceuticals and biotechnology. The combination means that the holdings and returns of IEIH may not match those of traditionally classified funds, so investors should use extra caution to be sure that holdings align with their investment objectives.
IEIH MSCI ESG Analytics Insight
iShares Evolved U.S. Innovative Healthcare ETF has an MSCI ESG Fund Rating of BBB based on a score of 4.31 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. iShares Evolved U.S. Innovative Healthcare ETF ranks in the 25th percentile within its peer group and in the 37th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
IEIH CHARTS AND PERFORMANCE
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
IEIH Top 10 Countries
IEIH Top 10 Sectors
IEIH Top 10 Holdings [View All]
IEIH Summary Data
IEIH Portfolio Data
IEIH Portfolio Management
IEIH Tax Exposures
IEIH Fund Structure
IEIH Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of IEIH. IEIH is rated a 5 out of 5.
IEIH Tradability
IEIH Sector/Industry Breakdown
IEIH
IEIH TOP 10 HOLDINGS[View All]
IEIH Countries
IEIH
IEIH Regions
IEIH
IEIH Economic Development
IEIH
IEIH Performance Statistics
IEIH MSCI ESG Ratings
IEIH BENCHMARK COMPARISON SUMMARY
IEIH
IEIH BENCHMARK COMPARISON MARKET CAP SIZE
IEIH
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.